SCHEMBL189224

SCHEMBL189224

COC(=O)c1ccc(CCl)o1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.73
HPGD P15428 2/20 0.63
SMN1; SMN2 Q16637 2/20 0.63
ALDH1A1 P00352 5/20 0.61
NPSR1 Q6W5P4 1/20 0.61
RAB9A P51151 4/20 0.58
TSHR P16473 3/20 0.58
NPC1 O15118 3/20 0.58
HSP90AA1 P07900 1/20 0.58
MAPT P10636 4/20 0.56
LMNA P02545 2/20 0.56
CYP2D6 P10635 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
HSD17B10 Q99714 2/20 0.54
KMT2A Q03164 2/20 0.52
POLB P06746 1/20 0.52
KDM4E B2RXH2 1/20 0.52
MEN1 O00255 1/20 0.52
MAPK1 P28482 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5756202 0.87 HTT (0.56) HTTHPGDSMN1; SMN2ALDH1A1NPSR1
SCHEMBL12018996 0.85 HTT (1.00) HTTHPGDSMN1; SMN2ALDH1A1NPSR1
SCHEMBL2031143 0.83 HTT (0.76) HTTHPGDSMN1; SMN2ALDH1A1NPSR1
SCHEMBL1530038 0.83 HTT (0.76) HTTHPGDSMN1; SMN2ALDH1A1NPSR1
SCHEMBL22680998 0.83 HTT (0.50) HTTHPGDSMN1; SMN2ALDH1A1NPSR1
SCHEMBL852957 0.82 ALDH1A1 (0.58) HTTHPGDSMN1; SMN2ALDH1A1RAB9A
SCHEMBL4444107 0.81 HTT (0.73) HTTHPGDSMN1; SMN2ALDH1A1NPSR1
SCHEMBL1327551 0.81 HTT (0.73) HTTHPGDSMN1; SMN2ALDH1A1NPSR1
SCHEMBL6441147 0.81 HTT (0.73) HTTHPGDSMN1; SMN2ALDH1A1NPSR1
SCHEMBL14008055 0.81 HTT (0.49) HTTHPGDSMN1; SMN2ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 517 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260090547-A1 BIO-INSECTICIDES FROM WASTE BIOMASS UNIVERSITY OF DELAWARE (US) 2026-04-02 US disclosed
US-12522618-B2 Copper complexes for treatment of neurodegenerative disorders ALS THERAPY DEVELOPMENT INSTITUTE (US) 2026-01-13 US disclosed
US-12459929-B2 GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use CARMOT THERAPEUTICS INC. (US) 2025-11-04 US disclosed
US-20250229198-A1 COMPOUNDS FOR SEPARATION OF RARE EARTH ELEMENTS AND S-, P-, D- METALS, METHOD OF SEPARATION, AND USE THEREOF USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I (CZ) 2025-07-17 US disclosed
EP-4563199-A2 GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE Carmot Therapeutics, Inc. (US) 2025-06-04 EP disclosed
US-20250154137-A1 GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE CARMOT THERAPEUTICS, INC. 2025-05-15 US disclosed
US-12268977-B2 Compounds for separation of rare earth elements and s-, p-, d-metals, method of separation, and use thereof USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR. V.V.I. (CZ) 2025-04-08 US disclosed
US-12195472-B2 Substituted indole Mcl-1 inhibitors VANDERBILT UNIVERSITY (US) 2025-01-14 US disclosed
US-20240368195-A1 COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS ALS THERAPY DEVELOPMENT INST (US) 2024-11-07 US disclosed
US-20240252492-A1 GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE CARMOT THERAPEUTICS, INC. 2024-08-01 US disclosed
US-4935442-A Tetrahydrofuran-containing macrocyclic polyether carboxylic acids PFIZER INC. (US) 1990-06-19 US disclosed
US-4866076-A THROMBOXANE ANTAGONISTS SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1989-09-12 US disclosed
US-4837316-A ANTIULCER AGENTS FUJIREBIO KABUSHIKI KAISHA (JP) 1989-06-06 US disclosed
CN-1031536-A 2 '-'-Deoxy-5-fluorouridine derivatives and its production and application OTSUKA PHARMA CO LTD (JP) 1989-03-08 CN disclosed
EP-0236624-A2 Substituted phenyl ethanol amines, processes for their preparation and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1987-09-16 EP disclosed
EP-0214823-A2 Alkylamide derivatives with H2-receptor antagonistic and cytoprotective action FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. (JP) 1987-03-18 EP disclosed
CN-85108623-A Preparation has the novel method of the heterocycleamide of medical active 1986-07-30 CN disclosed
EP-0179619-A1 Heterocyclic amides ICI AMERICAS INC. (US) 1986-04-30 EP disclosed
US-4282246-A Antidiabetic furancarboxylic and thiphenecarboxylic acids PFIZER INC. (US) 1981-08-04 US disclosed
US-4273782-A FOR USE IN CARDIOVASCULAR DISORDERS AND COMPLICATIONS OF DIABETES PFIZER INC. (US) 1981-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154137-A1 GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE GLP1R, GCGR, GIPR HTT 1246/4885HPGD 1729/4885SMN1; SMN2 2952/4885
US-20260090547-A1 BIO-INSECTICIDES FROM WASTE BIOMASS PTMS, DDT, BCHE HTT 2819/4885HPGD 2297/4885SMN1; SMN2 3070/4885
US-20240252492-A1 GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE GLP1R, GCGR, GIPR HTT 1246/4885HPGD 1729/4885SMN1; SMN2 2952/4885
US-12459929-B2 GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use GLP1R, GCGR, GIPR HTT 1246/4885HPGD 1729/4885SMN1; SMN2 2952/4885
US-20250229198-A1 COMPOUNDS FOR SEPARATION OF RARE EARTH ELEMENTS AND S-, P-, D- METALS, METHOD OF SEPARATION, AND USE THEREOF SCO2, SOD3, SLC39A3 HTT 4245/4885HPGD 2202/4885SMN1; SMN2 2494/4885
US-20240368195-A1 COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS SOD1, SMN1; SMN2, CLN6 HTT 9/4885HPGD 2845/4885SMN1; SMN2 2/4885
US-12195472-B2 Substituted indole Mcl-1 inhibitors MCL1, BCL2L1, BCL3 HTT 1155/4885HPGD 3158/4885SMN1; SMN2 2394/4885
US-12268977-B2 Compounds for separation of rare earth elements and s-, p-, d-metals, method of separation, and use thereof SCLY, SFXN1, PTCD3 HTT 4780/4885HPGD 821/4885SMN1; SMN2 1716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.